EAU GUIDELINES ON UROLITHIASIS

(Limited text update March 2020)

C. Türk (Chair), A. Neisius, C. Seitz, A. Skolarikos (Vice-chair), A. Petrik, K. Thomas Guidelines Associates: N.F. Davis, J.F. Donaldson, N. Grivas. R. Lombardo, Y. Ruhayel

Aetiology and classification

Urinary stones can be classified according to the following aspects: aetiology of stone formation, stone composition (mineralogy), stone size, stone location, and X-ray characteristics of the stone. The recurrence risk is basically determined by the disease or disorder causing the stone formation.

Risk groups for stone formation

The risk status of stone formers is of particular interest because it defines the probability of recurrence or regrowth, and is imperative for pharmacological treatment (Table 1).

Table 1: High-risk stone formers

factors

Early onset of urolithiasis (especially children and teenagers)

Familial stone formation

Brushite-containing stones (CaHPO4.2H2O)

Uric acid and urate-containing stones

Infection stones

Solitary kidney (the kidney itself does not particularly increase the risk of stone formation, but prevention of stone recurrence is of more importance)

Diseases associated with stone formation
Hyperparathyroidism
Metabolic syndrome
Nephrocalcinosis
Polycystic kidney disease (PKD)
Gastrointestinal diseases (i.e. jejuno-ileal bypass, intestinal resection, Crohn's disease, malabsorptive conditions, enteric hyperoxaluria after urinary diversion) and bariatric surgery
Sarcoidosis
Spinal cord injury, neurogenic bladder
Increased levels of vitamin D
Genetically determined stone formation
Cystinuria (type A, B and AB)
Primary hyperoxaluria (PH)
Renal tubular acidosis (RTA) type I
2,8-Dihydroxyadeninuria
Xanthinuria
Lesch-Nyhan syndrome
Cystic fibrosis
Drug-induced stone formation
Anatomical abnormalities associated with stone formation
Medullary sponge kidney (tubular ectasia)
Ureteropelvic junction (UPJ) obstruction
Calyceal diverticulum, calyceal cyst
Ureteral stricture
Vesico-uretero-renal reflux

Horseshoe kidney

Ureterocele

Environmental factors

High ambient tempertures

Chronic lead and cadmium exposure

Diagnostic Evaluation Diagnostic imaging

Standard evaluation of a patient includes taking a detailed medical history and physical examination. The clinical diagnosis should be supported by appropriate imaging.

Recommendation	Strength rating
Immediate imaging is indicated with fever	Strong
or solitary kidney, and when diagnosis is	
doubtful.	

Ultrasound (US) should be used as the primary diagnostic imaging tool, although pain relief, or any other emergency measures, should not be delayed by imaging assessments.

Kidney-ureter-bladder (KUB) urography should not be performed if non-contrast-enhanced computed tomography (NCCT) is being considered, but KUB urography can differentiate between radiolucent and radiopaque stones and should be used for comparison during follow up.

Recommendation for radiologic examinations of patients with acute flank pain/suspected ureteral stones	Strength rating
Use non-contrast-enhanced computed	Strong
tomography to confirm stone diagnosis in	
patients with acute flank pain, following	
initial ultrasound assessment.	

Recommendation for radiologic examination of patients with renal stones	Strength rating
Perform a contrast study if stone removal is	Strong
planned and the anatomy of the renal	_
collecting system needs to be assessed.	

Diagnostics: Metabolism-related

Each emergency patient with urolithiasis needs a succinct biochemical work-up of urine and blood; no difference is made between high- and low-risk patients.

Recommendations: basic laboratory analysis - emergency stone patients	Strength rating
Urine	
Dipstick test of spot urine sample:	Weak
red cells;	
white cells;	
nitrites;	
approximate urine pH;	
 urine microscopy and/or culture. 	
Blood	
Serum blood sample:	Weak
creatinine;	
uric acid;	
(ionised) calcium;	
sodium;	
potassium;	
blood cell count;	
C-reactive protein.	
Perform a coagulation test (partial	Strong
thromboplastin time and international	
normalised ratio) if intervention is likely or	
planned.	

Examination of sodium, potassium, C-reactive protein (CRP), and blood coagulation time can be omitted if no intervention is planned in non-emergency stone patients. Patients at high risk for stone recurrences should undergo a more specific analytical programme (see section on Metabolic Evaluation).

Recommendations related to non-emergency stone analysis	Strength rating
Perform stone analysis in first-time formers using a valid procedure (X-ray diffraction or infrared spectroscopy).	Strong
Repeat stone analysis in patients presenting with: recurrent stones despite drug therapy; early recurrence after complete stone clearance; late recurrence after a long stone-free period because stone composition may change.	Strong

Diagnosis for special groups/conditions Pregnancy

Recommendations	Strength rating
Use ultrasound as the preferred method of	Strong
imaging in pregnant women.	
In pregnant women, use magnetic	Strong
resonance imaging as a second-line	
imaging modality.	
In pregnant women, use low-dose	Strong
computed tomography as a last-line option.	

Children

Recommendations	Strength rating
Complete a metabolic evaluation based on	Strong
stone analysis, in all children.	
Collect stone material for analysis to	Strong
classify the stone type.	
Perform ultrasound (US) as first-line	Strong
imaging modality in children when a stone	
is suspected; it should include the kidney,	
fluid-filled bladder and the ureter.	
Perform a kidney-ureter-bladder	Strong
radiography (or low-dose non-contrast-	
enhanced computed tomography) if US will	
not provide the required information.	

In children, the most common non-metabolic disorders facilitating stone formation are vesico-ureteral reflux, ureteropelvic junction obstruction (UPJ), neurogenic bladder, and other voiding difficulties.

The radiation dose for intravenous urography (IVU) is comparable to that for voiding cysto-urethrography, but the need for contrast medium injection is a major drawback.

Disease Management

Acute treatment of a patient with renal colic

Pain relief is the first therapeutic step in patients with an acute stone episode.

Recommendations	Strength rating
Offer a non-steroidal anti-inflammatory as	Strong
the first drug of choice; e.g. metamizol*	
(dipyrone); alternatively paracetamol or,	
depending on cardiovascular risk factors,	
diclofenac**, indomethacin or ibuprofen***.	
Offer opiates (hydromorphine, pentazocine	Weak
or tramadol) as a second choice.	
Offer renal decompression or uretero-	Strong
scopic stone removal in case of analgesic	
refractory colic pain.	

- * Maximum single oral dose recommended 1,000 mg, total daily dose up to 5,000 mg, not recommended last 3 months of pregnancy and breastfeeding (EMA, Dec. 2018).
- ** Affects alomerular filtration rate (GFR) in patients with reduced renal function.
- *** Recommended to counteract recurrent pain after ureteral colic.

Administration of daily α -blockers seems to reduce colic episodes, although controversy remains in the published literature

If analgesia cannot be achieved medically, drainage, using stenting or percutaneous nephrostomy or stone removal, should be performed.

Management of sepsis and anuria in the obstructed kidney

The obstructed, infected, kidney is a urological emergency.

Based on an analysis of available evidence, an exact cut-off size for stones that are likely to pass spontaneously cannot be provided; < 10 mm may be considered a best estimate [203]. Therefore, the Panel decided not to include stone size but rather recommend "small". suggesting < 6 mm

Recommendations	Strength rating
Urgently decompress the collecting system	Strong
in case of sepsis with obstructing stones,	
using percutaneous drainage or ureteral	
stenting.	
Delay definitive treatment of the stone until	Strong
sepsis is resolved.	

In exceptional cases, with severe sepsis and/or the formation of abscesses, an emergency nephrectomy may become necessary.

Recommendations – Further measures	Strength rating
Collect (again) urine for antibiogram test	Strong
following decompression.	
Start antibiotics immediately (+ intensive	Strong
care, if necessary).	
Re-evaluate antibiotic regimen following	Strong
antibiogram findings.	

Medical expulsive therapy (MET)

Medical expulsive therapy should only be used in informed patients. Treatment should be discontinued if complications develop (infection, refractory pain, deterioration of renal function).

Medical expulsive therapy, using α -blockers, seems to be efficacious treating patients with ureteric stones that are amenable to conservative management. Patients benefitting most might be those with larger (distal) stones.

There is no or insufficient evidence to support the use of phosphodiesterase type 5 inhibitor (PDE-5i) or corticosteroids in combination with α -blockers as a standard adjunct to active stone removal.

Recommendation for medical expulsive therapy (MET)	Strength rating
Offer α-blockers as medical expulsive	Strong
therapy as one of the treatment options for	
(distal) ureteral stones > 5 mm.	

Chemolytic dissolution of stones

Oral chemolysis of stones or their fragments can be useful in uric acid stones. It is based on alkalinisation of urine by application of alkaline citrate or sodium bicarbonate. The pH should be adjusted to 7.0-7.2.

Percutaneous irrigation chemolysis is rarely used any more.

Recommendations – Oral chemolysis of uric acid stones	Strength rating
Inform the patient how to monitor urine-pH by dipstick and to modify the dosage of alkalising medication according to urine pH, as changes in urine pH are a direct consequence of such medication.	Strong
Carefully monitor patients during/after oral chemolysis of uric acid stones.	Strong
Combine oral chemolysis with tamsulosin in case of (larger) ureteral stones (if active intervention is not indicated).	Weak

Shock Wave lithotripsy (SWL)

The success rate for SWL will depend on the efficacy of the lithotripter and on:

- size, location (ureteral, pelvic or calyceal), and composition (hardness) of the stones:
- patient's habitus:
- performance of SWL.

Contraindications of SWL

Contraindications are few, but include:

- pregnancy;
- bleeding diatheses; which should be compensated for at least 24 hours before and 48 hours after treatment;
- · untreated urinary tract infections (UTIs);
- severe skeletal malformations and severe obesity, which prevent targeting of the stone;
- · arterial aneurysm in the vicinity of the stone;
- anatomical obstruction distal to the stone.

Best clinical practice (best performance) in SWL

Stenting prior to SWL

Routine use of internal stents before SWL does not improve stone-free rates (SFRs), nor lowers the number of auxiliary treatments. It may, however, reduce formation of steinstrasse.

Pacemaker

Patients with a pacemaker can be treated with SWL. Patients with implanted cardioverter defibrillators must be managed with special care (firing mode temporarily reprogrammed during SWL treatment). However, this might not be necessary with new-generation lithotripters.

Shock waves, energy setting and repeat treatment sessions

- The number of shock waves that can be delivered at each session depends on the type of lithotripter and shock wave power.
- Starting SWL on a lower energy setting with step-wise power ramping prevents renal injury.
- Optimal shock wave frequency is 1.0 to 1.5 Hz.
- Clinical experience has shown that repeat sessions are feasible (within one day for ureteral stones).

Procedural control

Recommendations - Procedural control	Strength rating
Ensure correct use of the coupling agent	Strong
because this is crucial for effective shock	
wave transportation.	
Maintain careful fluoroscopic and/or	Strong
ultrasonographic monitoring during shock	
wave lithotripsy.	
Use proper analgesia because it improves	Strong
treatment results by limiting pain-induced	
movements and excessive respiratory	
excursions.	

Antibiotic prophylaxis

No standard prophylaxis prior to SWL is recommended.

Recommendation	Strength rating
Prescribe antibiotics prior to shock wave	Strong
lithotripsy in the case of infected stones or	
bacteriuria.	

Ureteroscopy (URS) (retrograde and antegrade, RIRS)

Apart from general problems, for example, with general anaesthesia or untreated UTIs, URS can be performed in all patients without any specific contraindications.

If ureteral access is not possible, insertion of a JJ stent followed by URS after several days is an alternative. During URS, placement of a safety wire is recommended, even though some groups have demonstrated that URS can be performed without it.

Ureteral access sheaths allow easy, multiple, access to the upper urinary tract; however, its insertion may lead to ureteral trauma.

Recommendations	Strength rating
Use holmium:yttrium-aluminium-garnet	Strong
(Ho:YAG) laser lithotripsy for (flexible)	
ureteroscopy (URS).	
Perform stone extraction only under direct	Strong
endoscopic visualisation of the stone.	
Do not insert a stent in uncomplicated	Strong
cases.	
Pre-stenting facilitates URS and improves	Strong
outcomes of URS (in particular for renal	
stones).	
Offer medical expulsive therapy for patients	Strong
suffering from stent-related symptoms and	
after Ho:YAG laser lithotripsy to facilitate	
the passage of fragments.	

Percutaneous nephrolithotomy (PNL)

Patients with bleeding diathesis or receiving anticoagulant therapy must be monitored carefully pre- and post-operatively. Anticoagulant therapy must be discontinued before PNL.

Contraindications to PNL include:

- untreated UTI;
- · tumour in the presumptive access tract area;
- potential malignant kidney tumour;
- pregnancy.

Best clinical practice

Both prone and supine positions are equally safe. Percutaneous nephrolithotomy performed with small instruments tends to be associated with significantly lower blood loss, but the duration of procedure tends to be significantly longer.

Recommendations	Strength rating
Perform pre-procedural imaging, including	Strong
contrast medium where possible or	
retrograde study when starting the	
procedure, to assess stone comprehensive-	
ness and anatomy of the collecting system	
to ensure safe access to the renal stone.	
Perform a tubeless (without nephrostomy	Strong
tube) or totally tubeless (without	
nephrostomy tube and ureteral stent)	
percutaneous nephrolithotomy procedure,	
in uncomplicated cases.	

Stone Removal

Recommendations	Strength rating
Obtain a urine culture or perform urinary microscopy before any treatment is planned.	Strong
Exclude or treat urinary tract infections prior to stone removal.	Strong
Offer peri-operative antibiotic prophylaxis to all patients undergoing endourological treatment.	Strong
Offer active surveillance to patients at high risk of thrombotic complications in the presence of an asymptomatic calyceal stone.	Weak
Decide on temporary discontinuation, or bridging of antithrombotic therapy in high-risk patients, in consultation with the internist.	Strong

Retrograde (flexible) ureteroscopy is the preferred intervention if stone removal is essential and antithrombotic therapy cannot be discontinued, since it is	Strong
associated with less morbidity.	

Radiolucent uric acid stones can be dissolved by oral chemolysis.

Ureteral stones

Observation of ureteral stones is feasible in informed patients who develop no complications (infection, refractory pain, deterioration of kidney function).

Recommendations	Strength rating
In patients with newly diagnosed small*	Strong
ureteral stones, if active removal is not	
indicated, observe patient initially with	
periodic evaluation.	
Offer α -blockers as medical expulsive	Strong
therapy as one of the treatment options for	
(distal) ureteral stones > 5 mm.	
Inform patients that ureteroscopy (URS)	Strong
has a better chance of achieving stone-free	
status with a single procedure.	
Inform patients that URS has higher	Strong
complication rates when compared to	
shock wave lithotripsy.	
In cases of severe obesity use URS as	Strong
first-line therapy for ureteral (and renal)	
stones.	


^{*}See stratification data (J Urol, 2007. 178: 2418).

Indication for active stone removal and selection of procedure Ureter:

- stones with a low likelihood of spontaneous passage;
- persistent pain despite adequate pain medication;
- persistent obstruction:
- renal insufficiency (renal failure, bilateral obstruction, single kidney).

The suspected stone composition might influence the choice of treatment modality.

Figure 1: Treatment algorithm for ureteral stones (If active stone removal is indicated) (Strength rating: Strong)



SWL = shock wave lithotripsy; URS = ureteroscopy.

Recommendation	Strength rating
Use percutaneous antegrade removal of	Strong
ureteral stones as an alternative when	
shock wave lithotripsy is not indicated or	
has failed, and when the upper urinary	
tract is not amenable to retrograde	
ureteroscopy.	

Renal stones

It is still debatable whether all stones should be treated, or whether annual follow-up is sufficient for asymptomatic calyceal stones that have remained stable for six months.

Recommendations	Strength rating
Follow-up periodically in cases where renal stones are not treated (initially after six months then yearly, evaluating symptoms and stone status [either by ultrasound, kidney-ureter bladder radiography or computed tomography]).	Strong
Offer active treatment for renal stones in case of stone growth, <i>de novo</i> obstruction, associated infection, and acute and/or chronic pain.	Weak
Evaluate stone composition before deciding on the method of removal, based on patient history, former stone analysis of the patient or Hounsfield unit (HU) on unenhanced computed tomography (CT). Stones with density > 1,000 HU on noncontrast-enhanced CT are less likely to be disintegrated by shock wave lithotripsy.	Strong
Perform PNL as first-line treatment of larger stones > 2 cm.	Strong

Treat larger stones (> 2 cm) with flexible	Strong
ureteroscopy or SWL, in cases where PNL is	
not an option. However, in such instances	
there is a higher risk that a follow-up	
procedure and placement of a ureteral	
stent may be needed.	
Perform PNL or RIRS for the lower pole,	Strong
even for stones < 1 cm, as the efficacy	
of SWL is limited (depending on	
favourable and unfavourable factors for	
OLATI X	

SWL).


Indication for active stone removal and selection of procedure

Kidney:

- stone growth;
- stones in high-risk patients for stone formation;
- obstruction caused by stones;
- · infection;
- · symptomatic stones (e.g. pain, haematuria);
- stones > 15 mm;
- stones < 15 mm if observation is not the option of choice;
- patient preference;
- · comorbidity;
- social situation of the patient (e.g., profession or travelling).

The suspected stone composition might influence the choice of treatment modality.

Figure 2: Treatment algorithm for renal stones (if active treatment is indicated) (Strength rating: Strong)



^{*} The term 'endourology' encompasses all PNL and URS interventions.

PNL = percutaneous nephrolithotomy; RIRS = retrograde renal surgery; SWL = shock wave lithotripsy; URS = ureteroscopy.

Recommendation	Strength rating
Use flexible ureteroscopy in cases where	Strong
percutaneous nephrolithotomy or shock	
wave lithotripsy are not an option (even for	
stones > 2 cm). However, in this case there	
is a higher risk that a follow-up procedure	
and placement of a ureteral stent may be	
needed.	

Open and laparoscopic surgery

Recommendation	Strength rating
Offer laparoscopic or open surgical stone	Strong
removal in rare cases in which shock wave	
lithotripsy, retrograde or antegrade	
ureteroscopy and percutaneous	
nephrolithotomy fail, or are unlikely to be	
successful.	

Steinstrasse

The major factor in steinstrasse formation is stone size. Medical expulsion therapy increases the stone expulsion rate of steinstrasse. When spontaneous passage is unlikely, further treatment of steinstrasse is indicated.

Recommendations	Strength rating
Treat steinstrasse associated with urinary	Weak
tract infection (UTI)/fever preferably with	
percutaneous nephrostomy.	
Treat steinstrasse when large stone	Weak
fragments are present with shock wave	
lithotripsy or ureteroscopy (in absence of	
signs of UTI).	

Management of patients with residual stones

Following initial treatment with SWL, URS or PNL residual fragments may remain and require additional intervention. The indications for active removal of residual stones and selection of the procedure are based on the same criteria as for primary stone treatment. For well-disintegrated stone material in the lower calyx, inversion therapy with simultaneous mechanical percussion manoeuvre under enforced diuresis may facilitate stone clearance.

Recommendation in case of residual fragments	Strength rating
Perform imaging after shock wave	Strong
lithotripsy, ureteroscopy or percutaneous	
antegrade ureteroscopy to determine	
presence of residual fragments.	

Management of urinary stones and related problems during pregnancy

Recommendation	Strength rating
Treat all uncomplicated cases of	Strong
urolithiasis in pregnancy conservatively	
(except where there are clinical indication	ns
for intervention).	

If intervention becomes necessary, placement of a ureteral stent or a percutaneous nephrostomy tube are readily available primary options. Ureteroscopy is a reasonable alternative to avoid long-term stenting/drainage. There is a higher tendency for stent encrustation during pregnancy.

Management of stones in patients with urinary diversion

Patients with urinary diversion are at high risk for stone formation in the renal collecting system and ureter, or in the conduit or continent reservoir

Recommendation	Strength rating
Perform percutaneous lithotomy to remove	Strong
large renal stones in patients with urinary	
diversion, as well as for ureteral stones	
that cannot be accessed via a retrograde	
approach, or that are not amenable to	
shock wave lithotripsy.	

Management of stones in patients with neurogenic bladder

Patients with neurogenic bladder are more prone to development of urinary calculi.

In myelomeningocele patients, latex allergy is common so appropriate measures need to be taken regardless of the treatment

Management of stones in transplanted kidneys

Transplanted patients are at additional risk due to their dependency on a solitary kidney, immunosuppression therapy and possible metabolic impairments. Conservative treatment for small asymptomatic stones is only possible under close surveillance and in absolutely compliant patients.

Stones causing urinary stasis/obstruction require immediate intervention or drainage of the transplanted kidney.

Recommendation	Strength rating
Offer patients with transplanted kidneys,	Weak
any of the contemporary management	
options, including shock wave lithotripsy,	
flexible ureteroscopy and percutaneous	
nephrolithotomy.	

Special problems in stone removal

Calyceal	 Shock wave lithotripsy (SWL),
diverticulum	percutaneous nephrolithotomy (PNL)
stones	(if possible) or retrograde renal surgery (RIRS).
	 Laparoscopic retroperitoneal surgery.
	 Patients may become asymptomatic
	due to stone disintegration (SWL),
	whilst well-disintegrated stone material
	remains in the original position due to
	narrow calyceal neck.
Horseshoe	Can be treated in line with the options
kidneys	described above.
	Passage of fragments after SWL might
	be poor.
	Acceptable stone-free rates (SFRs) can
	be achieved with flexible ureteroscopy.
Stones in	SWL, RIRS, PNL or laparoscopic surgery.
pelvic kidneys	 In obese patients, the options are RIRS,
	PNL or open surgery.
Stones formed	Each stone must be considered and
in a continent	treated individually.
reservoir	_

Patients with obstruction of the ureteropelvic junction (UPJ)

- When outflow abnormality requires correction, stones can be removed by PNL together with percutaneous endopyelotomy or open/laparoscopic reconstructive surgery.
- Ureteroscopy together with endopyelotomy with holmium:vttriumaluminium-garnet laser.
- Incision with an Acucise® balloon catheter might be considered, provided the stones can be prevented from falling into the pelvic-ureteral incision.
- Open surgery with correction of the UPJ obstruction (pyeloplasty) and stone removal is a feasible option.

Management of urolithiasis in children

In children, the indication for SWL and for PNL is similar to those in adults. Compared to adults, children pass fragments more rapidly after SWL. For endourological procedures, the smaller organs in children must be considered when selecting instruments for PNL or URS.

Children with renal stones of a diameter up to 20 mm (~300 mm²) are ideal candidates for SWL.

Recommendations	Strength rating
Offer children with single ureteral stones	Strong
less than 10 mm shock wave lithotripsy	
(SWL) if localisation is possible as first-line	
option.	
Ureteroscopy is a feasible alternative for	Strong
ureteral stones not amenable to SWL.	
Offer children with renal stones with a	Strong
diameter of up to 20 mm (~300 mm ²) SWL.	
Offer children with renal pelvic or calyceal	Strong
stones with a diameter > 20 mm (~300 mm ²)	
percutaneous nephrolithotomy.	
Retrograde renal surgery is a feasible	Weak
alternative for renal stones smaller than	
20 mm in all locations.	

Metabolic evaluation and recurrence prevention

After stone passage, every patient should be assigned to a low- or high-risk group for stone formation. For correct classification, two analyses are mandatory:

- reliable stone analysis by infrared spectroscopy or X-ray diffraction;
- · basic analysis.

Only high-risk stone formers require specific metabolic evaluation. Stone type is the deciding factor for further diagnostic tests. For both groups, general preventive measures apply (see below).

General preventive measures	
Fluid intake (drinking advice)	 Fluid amount: 2.5-3.0 L/day Circadian drinking Neutral pH beverages Diuresis: 2.0-2.5 L/day Specific weight of urine: < 1,010 L/day
Nutritional advice for a balanced diet	Rich in vegetables and fibre Normal calcium content: 1-1.2 g/day Limited NaCl content: 4-5 g/day Limited animal protein content: 0.8-1.0 g/kg/day Avoid excessive consumption of vitamin supplements
Lifestyle advice to normalise general risk factors	Body mass index (BMI): Retain a normal BMI level Adequate physical activity Balancing of excessive fluid loss

Caution: Protein need is age-group dependent; therefore, protein restriction in childhood should be handled carefully.


Calcium oxalate stones

Hyperparathyroidism is excluded by blood analysis.

Recommendations for pharmacological treatment of patients with specific abnormalities in urine composition (based on 24-hour urine samples)

Urinary risk factor	Suggested treatment	Strength rating
Hypercalcuria	Thiazide + alkaline citrate	Strong
Hyperoxaluria	Oxalate restriction	Weak
Enteric	Potassium citrate	Weak
hyperoxaluria	Calcium supplement	Weak
	Diet reduced in fat and oxalate	Weak
Hypocitraturia	Alkaline citrate	Strong
Hypocitraturia	Sodium bicarbonate if intolerant to alkaline citrate	Strong
Hyperuricosuria	Allopurinol	Strong
	Febuxostat	Strong
High sodium excretion	Restricted intake of salt	Strong
Small urine volume	Increased fluid intake	Strong
Urea level indicating a high intake of animal protein	Avoid excessive intake of animal protein	Strong

Figure 3: Diagnostic and therapeutic algorithm for calcium oxalate stones



¹ Be aware of excess calcium excretion


 $^{^{2}}$ tid = three times/day (24h).

³ No magnesium therapy for patients with renal insufficiency

⁴ There is no evidence that combination therapy (thiazide + citrate) or (thiazide + allopurinol) is superior to thiazide therapy alone.

⁵ Febuxostat 80 mg/day.

Figure 4: Diagnostic and therapeutic algorithm for calcium phosphate stones




HPT = hyperparathyroidism; RTA = renal tubular acidosis; UTI = urinary tract infection.

Recommendations	Strength rating
Prescribe thiazide in case of hypercalciuria.	Strong
Advise patients to acidify their urine in case	Weak
of high urine pH.	

Hyperparathyroidism

Elevated levels of ionised calcium in serum (or total calcium and albumin) require assessment of intact parathyroid hormone to confirm or exclude suspected hyperparathyroidism (HPT). Primary HPT can only be cured by surgery.


Figure 5: Diagnostic and therapeutic algorithm for uric acid and urate-containing stones



UTI = urinary tract infection.

- 1 d: day
- ² tid: three times a day
- ³ A higher pH may lead to calcium phosphate stone formation.
- ⁴ In patients with high uric acid excretion, allopurinol may be helpful.

Figure 6: Metabolic management of cystine stones



Struvite/infection stones

Recommendations for therapeutic measures of infection stones	Strength rating
Surgically remove the stone material as completely as possible.	Strong
Prescribe antibiotics in case of persistent bacteriuria.	Strong
Prescribe ammonium chloride, 1 g, two or three times daily, to ensure urinary acidification.	Weak
Prescribe methionine, 200-500 mg, one to three times daily, as an alternative, to ensure urinary acidification.	Weak

2,8-Dihydroyadenine stones and xanthine stones

Both stone types are rare. In principle, diagnosis and specific prevention is similar to that of uric acid stones.

Drug stones

Drug stones are induced by pharmacological treatment. Two types exist:

- stones formed by crystallised compounds of the drug;
- · stones formed due to unfavourable changes in urine composition under drug therapy.

Treatment includes general preventive measures and the avoidance of the respective drugs.

Investigation	Rationale for investigation	
Medical history	Stone history (former stone events,	
_	family history)	
	Dietary habits	
	Medication chart	
Diagnostic	Ultrasound in the case of a suspected	
imaging	stone	
	 Unenhanced helical computed 	
	tomography	
	 Determination of Hounsfield units 	
	provides information about the	
	possible stone composition	
Blood analysis	Creatinine	
_	Calcium (ionised calcium or total	
	calcium + albumin)	
	Uric acid	
Perform a	Urine pH profile (measurement after	
urinalysis	each voiding, minimum four times daily)	
	Dipstick test: leukocytes, erythrocytes,	
	nitrites, protein, urine pH, specific weight	
	Urine cultures	
	Microscopy of urinary sediment	
	(morning urine)	
	Cyanide nitroprusside test (cystine	
	exclusion). Further examinations depend	
	on the results of the investigations	
	listed above.	

Further examinations depend on the results of the investigations listed above.

This short booklet text is based on the more comprehensive EAU Guidelines (ISBN 978-94-92671-07-03) available to all members of the European Association of Urology at their website, http://www.uroweb.org/guidelines/.